Reset Mind Sciences was incorporated on 28 May 2021 in Western Australia as a wholly-owned subsidiary of Little Green Pharma, a vertically integrated medicinal cannabis company, to focus specifically on psychedelic medicines.
Reset Mind Sciences has sought to capitalise on Little Green Pharma’s knowledge, track record, infrastructure and regulatory approvals to pursue a business in the field of psychedelic medicines. It plans to continue to leverage this relationship into the future with Reset Mind Sciences to have exclusive access to LGP’s Schedule 9 licenced production facility for psilocybin production.
Reset sees itself as an industry-disruptor at the beginning of a breakthrough in mental health treatment – an entirely new breed of pharma-therapy company. Its vision is to help provide a meaningful new treatment option for mental health through the use of psychedelic medicines.
